New nanomedicine helps treat lung disease after stem cell transplants
A new treatment restores metabolism to control inflammation while keeping immune defenses strong.
Researchers developed a nanomedicine called CaNAD + -PGB-LiP (CNAPL). This medicine helps treat chronic lung graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
The study found a collapse of an epithelial nicotinamide adenine dinucleotide (NAD + ) metabolic axis. This collapse causes pathogenic immune-epithelial remodeling in lung lesions.
Free NAD + is poorly cell-permeable and is rapidly consumed. CNAPL is a high-payload NAD + nanomedicine that enables direct intracellular replenishment.
In murine allo-HSCT GVHD, CNAPL improved clinical scores and survival. It reduced vascular and epithelial injury and curtailed hyperinflammation and effector overactivation.
Unlike immunosuppression, CNAPL preserved phagocytosis, NK/NKT cell (natural killer/natural killer T cell) cytotoxicity, and T cell memory. It maintained pathogen control during posttransplant influenza or Klebsiella infection without rekindling GVHD.
This metabolism-centered, host-directed strategy restores immune-tissue homeostasis. It provides a practical translational path for durable lung GVHD control with preserved antimicrobial defense.
Key facts
- CNAPL improves survival and clinical scores in murine allo-HSCT GVHD.
- The nanomedicine restores NAD + to resolve the inflammation-immunocompetence trade-off.
- CNAPL maintains pathogen control during influenza or Klebsiella infection.